Treatment of Richter transformation - immunotherapy to the rescue?
Mené sur 28 patients présentant un syndrome de Richter (durée médiane de suivi : 16,8 mois), cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité d'un traitement combinant atézolizumab, vénétoclax et obinutuzumab
Richter transformation describes the development of an aggressive lymphoma in patients with chronic lymphocytic leukaemia, most commonly into a diffuse large B-cell lymphoma (DLBCL).1 In contrast to the substantial advances in treatments for chronic lymphocytic leukaemia, which have contributed to improved survival outcomes in these patients, the prognosis for patients with Richter transformation remains dismal. Response to chemotherapeutic approaches that mirror de-novo DLBCL therapy is poor, and 1-year overall survival rates are lower than 50%
The Lancet Oncology 2023